Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 30;14(7):e250116.
doi: 10.1530/EC-25-0116. Print 2025 Jul 1.

BRAF V600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression

BRAF V600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression

Nguyen Thi Nhung et al. Endocr Connect. .

Abstract

Papillary thyroid carcinoma (PTC) is the most prevalent histological subtype of thyroid cancer. However, it remains unclear whether BRAF V600E, TERT promoter (TERT-p), and certain pathological markers, such as loss of polarity/loss of cell cohesiveness (LOP/LCC), tall cells, mitotic count, and Ki-67 labeling index (LI) in recurrent tumors, are associated with clinical outcomes in patients with PTC after reoperation for recurrent PTC. This study investigates the impact of BRAF V600E and TERT-p mutations on progression-free survival (PFS) after reoperation for recurrent PTC. Cox regression analysis was employed to identify parameters associated with PFS. During a mean follow-up period of 27 months after reoperation, 39 patients (21.3%) experienced disease progression. Coexistence of BRAF V600E and TERT-p mutations (double mutation: Dmut) was observed in 21.3% of patients. TERT-p, Dmut, LOP/LCC (≥10%), mitotic count (≥3 per 2 mm2), and Ki-67 LI were found to be significantly associated with disease progression in unadjusted analyses. In a multivariable analysis, these associations remained significant, with hazard ratios and 95% confidence intervals for TERT-p, Dmut, LOP/LCC, mitotic count, and Ki-67 LI being 5.98 (2.31-15.5), 5.44 (2.21-13.3), 6.81 (2.00-23.2), 5.05 (2.07-12.3), and 5.85 (2.48-13.7), respectively. Extranodal extension was associated with disease progression in both unadjusted and multivariable analyses. TERT-p, Dmut, Ki-67 LI, LOP/LCC, mitotic count, and extranodal extension were identified as independent risk factors for poor PFS after reoperation. Close surveillance following reoperation is recommended for patients exhibiting these factors.

Keywords: TERT; disease progression; loss of polarity/loss of cell cohesiveness; mitosis; recurrent papillary thyroid carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the work reported.

Figures

Figure 1
Figure 1
Flow diagram showing the number of participants and description of the study design. PTC: papillary thyroid cancer, unstim-Tg: unstimulated thyroglobulin.
Figure 2
Figure 2
Loss of polarity/loss of cell cohesiveness (LOP/LCC) in the invasive front area (hematoxylin–eosin). (A) Solitary cells (arrowheads) and small nests (arrows), accompanied by desmoplastic changes. Scale bar indicates 240 μm. (B) Enlarged hyperchromatic nuclei in solitary cells arranged in irregular rows, accompanied by desmoplastic changes. Scale bar indicates 120 μm. (C) Large nests with micropapillary structures. Scale bar indicates 240 μm.
Figure 3
Figure 3
PFS using the Kaplan–Meier method, stratified by TERT promoter (A), double mutation (B), loss of polarity/loss of cell cohesiveness (LOP/LCC) (C), extranodal extension (D), mitotic count (E), and Ki-67 LI (F). There were significant differences in PFS between the two groups for each factor. All results are unadjusted PFS.

References

    1. Fagin JA & Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med 2016. 375 1054–1067. ( 10.1056/NEJMra1501993) - DOI - PMC - PubMed
    1. Mazzaferri EL & Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994. 97 418–428. ( 10.1016/0002-9343(94)90321-2) - DOI - PubMed
    1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016. 26 1–133. ( 10.1089/thy.2015.0020) - DOI - PMC - PubMed
    1. Boucai L, Zafereo M & Cabanillas ME. Thyroid cancer: a review. JAMA 2024. 331 425–435. ( 10.1001/jama.2023.26348) - DOI - PubMed
    1. Lee HS, Roh JL, Gong G, et al. Risk factors for re-recurrence after first reoperative surgery for locoregional recurrent/persistent papillary thyroid carcinoma. World J Surg 2015. 39 1943–1950. ( 10.1007/s00268-015-3052-2) - DOI - PubMed

LinkOut - more resources